Omeprazole
142 interactions 106 explained in plain English 955 cited referencesA proton-pump inhibitor used to treat acid reflux, heartburn, and stomach ulcers. Read the full Omeprazole drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Omeprazole Abametapir Explained Increased exposure of CYP3A4 substrate Details Omeprazole Acalabrutinib Calquence Reduced acalabrutinib exposure Details Omeprazole Amphetamine Dexedrine Explained Increased exposure to amphetamine Details Omeprazole Apalutamide Erleada Explained Reduced CYP2C19/CYP3A4 substrate exposure Details Omeprazole Atazanavir Reyataz Explained Reduced atazanavir exposure, reduced efficacy of atazanavir and development of resistance Details Omeprazole Atezolizumab Tecentriq Explained Impaired efficacy of atezolizumab Details Omeprazole Avacopan Tavneos Explained Increased CYP3A4 substrate exposure Details Omeprazole Belumosudil Rezurock Explained Reduced belumosudil exposure Details Omeprazole Belzutifan Welireg Explained Increased belzutifan exposure and an increased risk of belzutifan-related adverse reactions Details Omeprazole Benzphetamine Explained Increased exposure to amphetamine Details Omeprazole Bosutinib Bosulif Reduced bosutinib exposure Details Omeprazole Cannabidiol Epidiolex Explained Increased CYP2C19 substrate exposure and an increased risk of CYP2C19 substrate-related adverse reactions Details Omeprazole Capecitabine Xeloda Reduction in capecitabine efficacy Details Omeprazole Carbamazepine Carbatrol Explained Increased carBAMazepine exposure, an increased risk of carBAMazepine toxicity, reduced omeprazole exposure and reduced efficacy of... Details Omeprazole Cefuroxime Axetil Explained Decreased cefuroxime axetil exposure Details Omeprazole Cilostazol Pletal® Explained Increased cilostazol exposure Details Omeprazole Citalopram Celexa Explained Increased citalopram exposure and an increased risk of QT interval prolongation Details Omeprazole Clarithromycin Biaxin Explained Increased clarithromycin exposure in gastric tissue and mucus and an increased omeprazole exposure Details Omeprazole Clopidogrel Plavix Reduced clopidogrel active metabolite exposure and decreased antiplatelet activity Details Omeprazole Clorazepate Tranxene Explained An increased risk of clorazepate toxicity Details Omeprazole Conivaptan Vaprisol Explained Increased CYP3A substrate exposure Details Omeprazole Cyanocobalamin Dodex Reduced cyanocobalamin absorption Details Omeprazole Dabrafenib Tafinlar Explained Reduced CYP2C19 sensitive substrate exposure Details Omeprazole Dacomitinib Vizimpro Reduced dacomitinib exposure Details Omeprazole Darunavir Explained Altered (reduced/increased) omeprazole exposure, an increased darunavir-related adverse reactions and reduced efficacy of omeprazo... Details Omeprazole Dasabuvir Explained Increased dasabuvir concentration; decreased omeprazole concentration Details Omeprazole Dasatinib Phyrago Reduced dasatinib exposure Details Omeprazole Defactinib Explained Reduced defactinib exposure and an reduced efficacy of defactinib Details Omeprazole Delavirdine Rescriptor® Explained Reduced serum delavirdine levels Details Omeprazole Dextroamphetamine Dexedrine Explained Increased exposure to amphetamine Details Omeprazole Diazepam Diastat Explained Increased diazepam exposure Details Omeprazole Digoxin Cardoxin® Increased digoxin exposure, an increased risk of digoxin toxicity (nausea, vomiting, arrhythmias) and an increased risk of hypomag... Details Omeprazole Disulfiram Antabuse Altered disulfiram exposure and an increased risk of disulfiram toxicity (confusion, disorientation, psychotic changes) Details Omeprazole Elagolix Orilissa Explained Increased omeprazole exposure Details Omeprazole Erlotinib Tarceva Reduced erlotinib exposure Details Omeprazole Erythromycin Erythrocin Stearate Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse effects Details Omeprazole Escitalopram Lexapro Explained Increased escitalopram exposure Details Omeprazole Eslicarbazepine Acetate Aptiom Explained Increased exposure of CYP2C19 substrates Details Omeprazole Fedratinib Inrebic Explained Increased CYP3A4/CYP2C19 substrate exposure Details Omeprazole Fexinidazole Explained An increased CYP3A4 substrate exposure DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist